R
Ravindranath Patel
Researcher at University of California, Los Angeles
Publications - 24
Citations - 2341
Ravindranath Patel is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Letrozole & Breast cancer. The author has an hindex of 11, co-authored 24 publications receiving 1924 citations.
Papers
More filters
Journal ArticleDOI
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn,John Crown,István Láng,Katalin Boér,Igor Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Marcus Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,Camilla Fowst,Xin Huang,Sindy T. Kim,Sophia Randolph,Dennis J. Slamon +17 more
TL;DR: Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and synergy with anti-oestrogens as mentioned in this paper.
Journal ArticleDOI
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Charles S. Fuchs,Kohei Shitara,Maria Di Bartolomeo,Sara Lonardi,Salah-Eddin Al-Batran,Eric Van Cutsem,David H. Ilson,Maria Alsina,Ian Chau,Jill Lacy,Michel Ducreux,Michel Ducreux,Guillermo Mendez,Alejandro Molina Alavez,Daisuke Takahari,Wasat Mansoor,Peter C. Enzinger,Vera Gorbounova,Zev A. Wainberg,Susanna Hegewisch-Becker,David Ferry,Ji Lin,Roberto Carlesi,Mayukh Das,Manish A. Shah,Manish A. Shah,Alexander Luft,Nina A. Karaseva,Rubén Dario Kowalyszyn,Carlos Alberto Hernandez,Tibor Csoszi,Ferdinando De Vita,Per Pfeiffer,Naotoshi Sugimoto,Judit Kocsis,Andràs Csilla,György Bodoky,Georgina Garnica Jaliffe,Svetlana Protsenko,A Madi,Elzbieta Wojcik,Baruch Brenner,Gunnar Folprecht,Tomasz Sarosiek,Katriina Peltola,Peter Bono,Hubert Ayala,Giuseppe Aprile,Cardellino Giovanni Gerardo,Fidel David Huitzil Melendez,Alfredo Falcone,Francesco Di Costanzo,Moustapha Tehfe,Laurent Mineur,Pilar Garcia Alfonso,Radka Obermannova,Hélène Senellart,Russell D. Petty,Leslie Samuel,Peter Istvan Acs,Maen A. Hussein,Marina N. Nechaeva,F.L.G. Erdkamp,Elizabeth Won,Johanna C. Bendell,Javier Gallego Plazas,Sylvie Lorenzen,Bohuslav Melichar,Miguel Angel Escudero,Denis Pezet,Jean-Marc Phelip,Diego Lucas Kaen,James A. Jr Reeves,Federico Longo Munoz,Srinivasan Madhusudan,Carlo Barone,Luis Fein,Angel Gomez Villanueva,Mohamed Hebbar,Jana Prausová,Laura Visa Turmo,Joana Vidal Barrull,Mette Karen Yilmaz,Alex Beny,H.M.W. Van Laarhoven,Brian Anthony DiCarlo,Taito Esaki,Kazumasa Fujitani,Karen Geboes,Ravit Geva,Shigenori Kadowaki,Stephen Leong,Nozomu Machida,Moses Sundar Raj,Francisco Javier Ramirez Godinez,Agnes Ruzsa,Hugo Ford,William E. Lawler,Nicolas Robert Maisey,Jiri Petera,Einat Shacham-Shmueli,Isabelle Sinapi,Kensei Yamaguchi,Hiroki Hara,J.T. Beck,Maria Błasińska-Morawiec,Ricardo Villalobos Valencia,Thierry Alcindor,Madhuri Bajaj,Scott M. Berry,Christina Maria Gomez,Daniel Dammrich,Ravindranath Patel,Julien Taieb,A.J. Ten Tije,Ronald L. Burkes,Fernando Cabanillas,Irfan Firdaus,Cynthia Coo Chua,Shuichi Hironaka,Ralf-Dieter Hofheinz,Howard J. Lim,Marianne Nordsmark,Bela Piko,Udit Verma,Jonathan Wadsley,Seigo Yukisawa,Francisco Gutiérrez Delgado,Crystal S. Denlinger,Raija Kallio,Joanna Pikiel,Joanna Wojcik-Tomaszewska,Christine Brezden-Masley,Raymond Jang,Jana Pribylova,Daisuke Sakai,Maria Alejandra Bartoli,Annemieke Cats,M.I. Grootscholten,Robert Andrew Dichmann,Hugo Hool,Walid Shaib,Akihito Tsuji,Marc Van den Eynde,Hector Velez-Cortez,Timothy R. Asmis +145 more
TL;DR: The addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Proceedings ArticleDOI
Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)
Richard S. Finn,John Crown,István Láng,Katalin Boér,I. Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Maike Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,A Breazna,Sinil Kim,Sophia Randolph,DJ Slamon +16 more
TL;DR: The combination of PD 0 332991 and letrozole is well tolerated and shows encouraging clinical benefit, confirming the sensitivity of ER+ BC to PD 0332991 observed in preclinical models.
Journal ArticleDOI
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Richard S. Finn,John Crown,Johannes Ettl,Marcus Schmidt,Igor Bondarenko,István Láng,Tamás Pintér,Katalin Boér,Ravindranath Patel,Sophia Randolph,Sindy T. Kim,Xin Huang,Patrick Schnell,Sashi Nadanaciva,Cynthia Huang Bartlett,Dennis J. Slamon +15 more
TL;DR: The magnitude of clinical benefit seen with the addition of palbociclib to letrozole in improving both median PFS and clinical benefit response (CBR) rate is consistent in nearly all subgroups analyzed, and consistent with that seen in the overall study population.
Journal ArticleDOI
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
Zev A. Wainberg,LS Lin,B DiCarlo,K. M. Dao,Ravindranath Patel,David J. Park,He-Jing Wang,R. Elashoff,N. Ryba,J. R. Hecht +9 more
TL;DR: In patients with Eso/GEJ adenocarcinoma, mFOLFOX6 and erlotinib is active, has an acceptable toxicity profile and FOLFOX±erlotinIB could be considered for further development.